{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:16Z","timestamp":1792783096667,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["R21TR004006"],"award-info":[{"award-number":["R21TR004006"]}]},{"name":"NIH","award":["R01AR056973"],"award-info":[{"award-number":["R01AR056973"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10928-024-09910-1","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T12:02:11Z","timestamp":1712923331000},"page":"671-683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles"],"prefix":"10.1007","volume":"51","author":[{"given":"Deok Yong","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Willcocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Triplett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Francisco","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn A.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Rooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Vandenborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9179-0735","authenticated-orcid":false,"given":"Sarah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the DMD MR Biomarker Steering Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"issue":"3","key":"9910_CR1","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","volume":"5","author":"QQ Gao","year":"2015","unstructured":"Gao QQ, McNally EM (2015) The dystrophin complex: structure, function, and implications for therapy. Compr Physiol 5(3):1223\u20131239. https:\/\/doi.org\/10.1002\/cphy.c140048","journal-title":"Compr Physiol"},{"issue":"6","key":"9910_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51(6):919\u2013928. https:\/\/doi.org\/10.1016\/0092-8674(87)90579-4","journal-title":"Cell"},{"issue":"1","key":"9910_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13018-022-02996-8","volume":"17","author":"N Salari","year":"2022","unstructured":"Salari N, Fatahi B, Valipour E et al (2022) Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis. J Orthop Surg Res 17(1):96. https:\/\/doi.org\/10.1186\/s13018-022-02996-8","journal-title":"J Orthop Surg Res"},{"issue":"2","key":"9910_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/mus.27532","volume":"66","author":"S Thomas","year":"2022","unstructured":"Thomas S, Conway KM, Fapo O et al (2022) Time to diagnosis of Duchenne muscular dystrophy remains unchanged: findings from the muscular dystrophy surveillance, tracking, and research network, 2000\u20132015. Muscle Nerve 66(2):193\u2013197. https:\/\/doi.org\/10.1002\/mus.27532","journal-title":"Muscle Nerve"},{"issue":"3","key":"9910_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17(3):251\u2013267. https:\/\/doi.org\/10.1016\/S1474-4422(18)30024-3","journal-title":"Lancet Neurol"},{"issue":"12","key":"9910_CR6","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/archdischild-2014-306366","volume":"99","author":"HJ van Ruiten","year":"2014","unstructured":"van Ruiten HJ, Straub V, Bushby K, Guglieri M (2014) Improving recognition of Duchenne muscular dystrophy: a retrospective case note review. Arch Dis Child 99(12):1074\u20131077. https:\/\/doi.org\/10.1136\/archdischild-2014-306366","journal-title":"Arch Dis Child"},{"issue":"1","key":"9910_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/mus.23810","volume":"48","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Lloyd-Puryear M (2013) Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve 48(1):21\u201326. https:\/\/doi.org\/10.1002\/mus.23810","journal-title":"Muscle Nerve"},{"key":"9910_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950651","volume":"13","author":"J Deng","year":"2022","unstructured":"Deng J, Zhang J, Shi K, Liu Z (2022) Drug development progress in Duchenne muscular dystrophy. Front Pharmacol 13:950651. https:\/\/doi.org\/10.3389\/fphar.2022.950651","journal-title":"Front Pharmacol"},{"issue":"2","key":"9910_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/13543784.2021.1868434","volume":"30","author":"O Sheikh","year":"2021","unstructured":"Sheikh O, Yokota T (2021) Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies. Expert Opin Investig Drugs 30(2):167\u2013176. https:\/\/doi.org\/10.1080\/13543784.2021.1868434","journal-title":"Expert Opin Investig Drugs"},{"key":"9910_CR10","unstructured":"FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy (FDA NEWS RELEASE, Content current as of: 29 Sept 2016)"},{"issue":"7","key":"9910_CR11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","volume":"81","author":"M Shirley","year":"2021","unstructured":"Shirley M (2021) Casimersen: first approval. Drugs 81(7):875\u2013879. https:\/\/doi.org\/10.1007\/s40265-021-01512-2","journal-title":"Drugs"},{"issue":"3","key":"9910_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","volume":"80","author":"YA Heo","year":"2020","unstructured":"Heo YA (2020) Golodirsen: first approval. Drugs 80(3):329\u2013333. https:\/\/doi.org\/10.1007\/s40265-020-01267-2","journal-title":"Drugs"},{"issue":"10","key":"9910_CR13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Viltolarsen: first approval. Drugs 80(10):1027\u20131031. https:\/\/doi.org\/10.1007\/s40265-020-01339-3","journal-title":"Drugs"},{"issue":"17","key":"9910_CR14","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","volume":"76","author":"YY Syed","year":"2016","unstructured":"Syed YY (2016) Eteplirsen: first global approval. Drugs 76(17):1699\u20131704. https:\/\/doi.org\/10.1007\/s40265-016-0657-1","journal-title":"Drugs"},{"key":"9910_CR15","unstructured":"Lin G AF, Otuonya I. Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value-Evidence Report. 2019. Accessed 25 Apr 2023. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_DMD-Final-Report_081519-2-1.pdf"},{"issue":"1","key":"9910_CR16","first-page":"9","volume":"31","author":"C Angelini","year":"2012","unstructured":"Angelini C, Peterle E (2012) Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myol 31(1):9\u201315","journal-title":"Acta Myol"},{"issue":"12","key":"9910_CR17","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/humu.21114","volume":"30","author":"KM Flanigan","year":"2009","unstructured":"Flanigan KM, Dunn DM, von Niederhausern A et al (2009) Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 30(12):1657\u20131666. https:\/\/doi.org\/10.1002\/humu.21114","journal-title":"Hum Mutat"},{"issue":"3","key":"9910_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/mus.23905","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT et al (2013) The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48(3):357\u2013368. https:\/\/doi.org\/10.1002\/mus.23905","journal-title":"Muscle Nerve"},{"issue":"2","key":"9910_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/jnnp-2014-309405","volume":"87","author":"V Ricotti","year":"2016","unstructured":"Ricotti V, Ridout DA, Pane M et al (2016) The NorthStar ambulatory assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry 87(2):149\u2013155. https:\/\/doi.org\/10.1136\/jnnp-2014-309405","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"9910_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/jmri.22431","volume":"33","author":"M Gloor","year":"2011","unstructured":"Gloor M, Fasler S, Fischmann A et al (2011) Quantification of fat infiltration in oculopharyngeal muscular dystrophy: comparison of three MR imaging methods. J Magn Reson Imaging 33(1):203\u2013210. https:\/\/doi.org\/10.1002\/jmri.22431","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"9910_CR21","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1148\/radiol.10091547","volume":"255","author":"HK Kim","year":"2010","unstructured":"Kim HK, Laor T, Horn PS, Racadio JM, Wong B, Dardzinski BJ (2010) T2 mapping in Duchenne muscular dystrophy: distribution of disease activity and correlation with clinical assessments. Radiology 255(3):899\u2013908. https:\/\/doi.org\/10.1148\/radiol.10091547","journal-title":"Radiology"},{"issue":"8","key":"9910_CR22","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s00256-011-1301-5","volume":"41","author":"M Gaeta","year":"2012","unstructured":"Gaeta M, Messina S, Mileto A et al (2012) Muscle fat-fraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessments. Preliminary experience. Skeletal Radiol 41(8):955\u2013961. https:\/\/doi.org\/10.1007\/s00256-011-1301-5","journal-title":"Skeletal Radiol"},{"issue":"4","key":"9910_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00256-011-1240-1","volume":"41","author":"M Torriani","year":"2012","unstructured":"Torriani M, Townsend E, Thomas BJ, Bredella MA, Ghomi RH, Tseng BS (2012) Lower leg muscle involvement in Duchenne muscular dystrophy: an MR imaging and spectroscopy study. Skeletal Radiol 41(4):437\u2013445. https:\/\/doi.org\/10.1007\/s00256-011-1240-1","journal-title":"Skeletal Radiol"},{"issue":"3","key":"9910_CR24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/nbm.2851","volume":"26","author":"I Arpan","year":"2013","unstructured":"Arpan I, Forbes SC, Lott DJ et al (2013) T(2) mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: a cross-sectional study of lower leg muscles in 5\u201315-year-old boys with Duchenne muscular dystrophy. NMR Biomed 26(3):320\u2013328. https:\/\/doi.org\/10.1002\/nbm.2851","journal-title":"NMR Biomed"},{"issue":"5","key":"9910_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.nmd.2013.12.012","volume":"24","author":"RJ Willcocks","year":"2014","unstructured":"Willcocks RJ, Arpan IA, Forbes SC et al (2014) Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression. Neuromuscul Disord 24(5):393\u2013401. https:\/\/doi.org\/10.1016\/j.nmd.2013.12.012","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"9910_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194283","volume":"13","author":"AM Barnard","year":"2018","unstructured":"Barnard AM, Willcocks RJ, Finanger EL et al (2018) Skeletal muscle magnetic resonance biomarkers correlate with function and sentinel events in Duchenne muscular dystrophy. PLoS ONE 13(3):e0194283. https:\/\/doi.org\/10.1371\/journal.pone.0194283","journal-title":"PLoS ONE"},{"issue":"9","key":"9910_CR27","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1212\/WNL.0000000000009012","volume":"94","author":"AM Barnard","year":"2020","unstructured":"Barnard AM, Willcocks RJ, Triplett WT et al (2020) MR biomarkers predict clinical function in Duchenne muscular dystrophy. Neurology 94(9):e897\u2013e909. https:\/\/doi.org\/10.1212\/WNL.0000000000009012","journal-title":"Neurology"},{"issue":"10","key":"9910_CR28","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/psp4.13021","volume":"12","author":"S Kim","year":"2023","unstructured":"Kim S, Willcocks RJ, Daniels MJ et al (2023) Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials. CPT Pharmacomet Syst Pharmacol 12(10):1437\u20131449. https:\/\/doi.org\/10.1002\/psp4.13021","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"7","key":"9910_CR29","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/psp4.12973","volume":"12","author":"JF Morales","year":"2023","unstructured":"Morales JF, Muse R, Podichetty JT et al (2023) Disease progression joint model predicts time to type 1 diabetes onset: optimizing future type 1 diabetes prevention studies. CPT Pharmacomet Syst Pharmacol 12(7):1016\u20131028. https:\/\/doi.org\/10.1002\/psp4.12973","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"3","key":"9910_CR30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/psp4.12753","volume":"11","author":"K Lingineni","year":"2022","unstructured":"Lingineni K, Aggarwal V, Morales JF et al (2022) Development of a model-based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy. CPT Pharmacomet Syst Pharmacol 11(3):318\u2013332. https:\/\/doi.org\/10.1002\/psp4.12753","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"4","key":"9910_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM (2008) Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 35(4):401\u2013421. https:\/\/doi.org\/10.1007\/s10928-008-9094-4","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"9910_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","volume":"11","author":"M Bergstrand","year":"2009","unstructured":"Bergstrand M, Karlsson MO (2009) Handling data below the limit of quantification in mixed effect models. AAPS J 11(2):371\u2013380. https:\/\/doi.org\/10.1208\/s12248-009-9112-5","journal-title":"AAPS J"},{"issue":"3","key":"9910_CR33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.0b013e318225ab2e","volume":"77","author":"E Mazzone","year":"2011","unstructured":"Mazzone E, Vasco G, Sormani MP et al (2011) Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 77(3):250\u2013256. https:\/\/doi.org\/10.1212\/WNL.0b013e318225ab2e","journal-title":"Neurology"},{"issue":"21","key":"9910_CR34","doi-asserted-by":"publisher","first-page":"e2406","DOI":"10.1212\/wnl.0000000000201163","volume":"99","author":"AM Barnard","year":"2022","unstructured":"Barnard AM, Hammers DW, Triplett WT et al (2022) Evaluating genetic modifiers of Duchenne Muscular dystrophy disease progression using modeling and MRI. Neurology 99(21):e2406\u2013e2416. https:\/\/doi.org\/10.1212\/wnl.0000000000201163","journal-title":"Neurology"},{"issue":"15","key":"9910_CR35","doi-asserted-by":"publisher","first-page":"e1622","DOI":"10.1212\/wnl.0000000000009244","volume":"94","author":"WD Rooney","year":"2020","unstructured":"Rooney WD, Berlow YA, Triplett WT et al (2020) Modeling disease trajectory in Duchenne muscular dystrophy. Neurology 94(15):e1622\u2013e1633. https:\/\/doi.org\/10.1212\/wnl.0000000000009244","journal-title":"Neurology"},{"issue":"9307","key":"9910_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","volume":"359","author":"AE Emery","year":"2002","unstructured":"Emery AE (2002) The muscular dystrophies. Lancet 359(9307):687\u2013695. https:\/\/doi.org\/10.1016\/S0140-6736(02)07815-7","journal-title":"Lancet"},{"issue":"11","key":"9910_CR37","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1212\/wnl.0000000000000775","volume":"83","author":"I Arpan","year":"2014","unstructured":"Arpan I, Willcocks RJ, Forbes SC et al (2014) Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS. Neurology 83(11):974\u2013980. https:\/\/doi.org\/10.1212\/wnl.0000000000000775","journal-title":"Neurology"},{"issue":"10","key":"9910_CR38","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/dmcn.14623","volume":"62","author":"P van Dommelen","year":"2020","unstructured":"van Dommelen P, van Dijk O, de Wilde JA, Verkerk PH (2020) Early developmental milestones in Duchenne muscular dystrophy. Dev Med Child Neurol 62(10):1198\u20131204. https:\/\/doi.org\/10.1111\/dmcn.14623","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"9910_CR39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jxb\/10.2.290","volume":"10","author":"FJ Richards","year":"1959","unstructured":"Richards FJ (1959) A flexible growth function for empirical use. J Exp Bot 10(2):290\u2013301. https:\/\/doi.org\/10.1093\/jxb\/10.2.290","journal-title":"J Exp Bot"},{"issue":"1","key":"9910_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/forestscience\/19.1.2","volume":"19","author":"LV Pienaar","year":"1973","unstructured":"Pienaar LV, Turnbull KJ (1973) The Chapman-Richards generalization of Von Bertalanffy\u2019s growth model for basal area growth and yield in even\u2014aged stands. For Sci 19(1):2\u201322. https:\/\/doi.org\/10.1093\/forestscience\/19.1.2","journal-title":"For Sci"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-024-09910-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-024-09910-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-024-09910-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T07:04:38Z","timestamp":1732086278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-024-09910-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9910"],"URL":"https:\/\/doi.org\/10.1007\/s10928-024-09910-1","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"1 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no competing interests for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}